Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Baljevic M, Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Lentzsch S, Monge J, Kotb R, Bahlis NJ, White D, Chen CI, Sutherland HJ, Madan S, LeBlanc R, Sebag M, Venner CP, Bensinger WI, Biran N, DeCastro A, Van Domelen DR, Zhang C, Shah JJ, Shacham S, Kauffman MG, Bentur OS, Lipe B. Baljevic M, et al. Among authors: shah jj. EJHaem. 2022 Sep 30;3(4):1270-1276. doi: 10.1002/jha2.572. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467792 Free PMC article.
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Gounder MM, et al. Among authors: shah jj. J Clin Oncol. 2022 Aug 1;40(22):2479-2490. doi: 10.1200/JCO.21.01829. Epub 2022 Apr 8. J Clin Oncol. 2022. PMID: 35394800 Free PMC article. Clinical Trial.
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Kaufman JL, Mina R, Shah JJ, Laubach JP, Nooka AK, Lewis C, Gleason C, Sharp C, Harvey RD, Heffner LT, Richardson P, Lonial S, Orlowski RZ. Kaufman JL, et al. Among authors: shah jj. Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):797-803. doi: 10.1016/j.clml.2020.07.013. Epub 2020 Jul 25. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32819881 Free article. Clinical Trial.
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. Lee HC, et al. Among authors: shah jj. Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6. Blood Cancer J. 2019. PMID: 31575851 Free PMC article. Clinical Trial. No abstract available.
119 results